Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo HF, who have known coronary artery disease (CAD) and no angina, unless the patient is not eligible for revasculariza- tion of any kind. (Level of Evidence: C) Table 6. Recommendations for Biomarkers in HF Biomarker, Application Setting COR LOE References Natriuretic peptides Diagnosis or exclusion of HF Ambulatory, Acute I A 64 70,92 98 Prognosis of HF Ambulatory, Acute I A 69,71 76,96,99 106 Achieve GDMT Ambulatory IIa B 77 84 Guidance for acutely decompensated HF therapy Acute IIb C 107,108 Biomarkers of myocardial injury Additive risk stratification Acute, Ambulatory I A 85 88,96,101,104 115 Biomarkers of myocardial fibrosis Additive risk stratification Ambulatory IIb B 89 91 Acute IIb A 96,101,104,106 108,110,112 115 COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; and LOE, Level of Evidence. Table 7. 